Literature DB >> 10421068

The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration.

C S Straathof1, M J van den Bent, W J Loos, C J Vecht, J H Schellens.   

Abstract

The accumulation of the topoisomerase I inhibitor topotecan in brain tumor as well as in brain around tumor (BAT) and normal brain following an intravenous bolus of topotecan of 0.5 mg/kg was investigated in rats bearing a 9L glioma. Also the influence of dexamethasone (Dex) on the uptake of topotecan was examined. Tumor, BAT and brain tissue as well as whole blood were collected at 1 h after an i.v. bolus of topotecan. Concentrations of total topotecan in tumor, BAT and brain were quantified with high-performance liquid chromatography (HPLC) and compared with concentrations in plasma of total topotecan. In brain tumor tissue the mean total topotecan concentration was 96 +/- 33 ng/g which was 20-fold higher than the accumulation of topotecan in normal brain tissue. In BAT intermediate concentrations of 13 +/- 4.9 ng/g were reached. Mean total topotecan concentration in plasma was 100 +/- 25 ng/ml. We did not find an influence of Dex on the uptake of topotecan in either tissue. We conclude that high tissue concentrations of topotecan can be reached in experimental brain tumors in rats. This observation may be useful in the design of clinical studies with topotecan.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10421068     DOI: 10.1023/a:1006166716683

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  15 in total

1.  Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines.

Authors:  Y Hoki; A Fujimori; Y Pommier
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

Review 2.  Do anticancer agents reach the tumor target in the human brain?

Authors:  M G Donelli; M Zucchetti; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group.

Authors:  D Macdonald; G Cairncross; D Stewart; P Forsyth; C Sawka; N Wainman; E Eisenhauer
Journal:  Ann Oncol       Date:  1996-02       Impact factor: 32.976

Review 4.  Emerging drug treatments for solid tumours.

Authors:  J H Schellens; L C Pronk; J Verweij
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

5.  The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor.

Authors:  C S Straathof; M J van den Bent; J Ma; P I Schmitz; J M Kros; G Stoter; C J Vecht; J H Schellens
Journal:  J Neurooncol       Date:  1998-03       Impact factor: 4.130

6.  Temporal effects of dexamethasone on blood-to-brain and blood-to-tumor transport of 14C-alpha-aminoisobutyric acid in rat C6 glioma.

Authors:  W R Shapiro; E M Hiesiger; G A Cooney; G A Basler; L E Lipschutz; J B Posner
Journal:  J Neurooncol       Date:  1990-06       Impact factor: 4.130

7.  Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts.

Authors:  H S Friedman; P J Houghton; S C Schold; S Keir; D D Bigner
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Positron emission tomographic measurement of blood-to-brain and blood-to-tumor transport of 82Rb: the effect of dexamethasone and whole-brain radiation therapy.

Authors:  J O Jarden; V Dhawan; A Poltorak; J B Posner; D A Rottenberg
Journal:  Ann Neurol       Date:  1985-12       Impact factor: 10.422

9.  Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates.

Authors:  S M Blaney; D E Cole; F M Balis; K Godwin; D G Poplack
Journal:  Cancer Res       Date:  1993-02-15       Impact factor: 12.701

10.  Chemotherapeutic agent permeability to normal brain and delivery to avian sarcoma virus-induced brain tumors in the rodent: observations on problems of drug delivery.

Authors:  E A Neuwelt; P A Barnett; E P Frenkel
Journal:  Neurosurgery       Date:  1984-02       Impact factor: 4.654

View more
  7 in total

1.  Effects of topotecan treatment on nasal, buccal, and lingual mucosa in the rabbit: light and transmission electron microscopic evaluation.

Authors:  Nuray Bayar Muluk; F Figen Kaymaz; A Nur Cakar
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-10-25       Impact factor: 2.503

2.  A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas.

Authors:  P A Burch; A M Bernath; T L Cascino; B W Scheithauer; P Novotny; S Nair; J C Buckner; D M Pfeifle; J W Kugler; L K Tschetter
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

Review 3.  Pharmacokinetic considerations in the treatment of CNS tumours.

Authors:  Susannah Motl; Yanli Zhuang; Christopher M Waters; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  Cytotoxic chemotherapy: advances in delivery, pharmacology, and testing.

Authors:  R Ciordia; J Supko; M Gatineau; T Batchelor
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

Review 5.  Glucocorticoids in the management of peritumoral brain edema: a review of molecular mechanisms.

Authors:  Roger Murayi; Prashant Chittiboina
Journal:  Childs Nerv Syst       Date:  2016-09-09       Impact factor: 1.475

6.  Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study.

Authors:  Thierry Lesimple; Laurent Riffaud; Didier Frappaz; Mohamed Ben Hassel; Daniel Gédouin; Jacques-Olivier Bay; Claude Linassier; Abderrahmane Hamlat; Gilles Piot; Michel Fabbro; Stéphan Saïkali; Béatrice Carsin; Yvon Guégan
Journal:  J Neurooncol       Date:  2009-01-13       Impact factor: 4.130

Review 7.  Drug interactions at the blood-brain barrier: fact or fantasy?

Authors:  Sara Eyal; Peng Hsiao; Jashvant D Unadkat
Journal:  Pharmacol Ther       Date:  2009-04-22       Impact factor: 13.400

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.